Regeneron Pharmaceuticals, Inc. $REGN Stake Raised by Lido Advisors LLC

Lido Advisors LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 26.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,677 shares of the biopharmaceutical company’s stock after buying an additional 3,030 shares during the quarter. Lido Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $11,129,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in REGN. Cornerstone Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $254,000. Csenge Advisory Group bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $237,000. Kestra Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals by 2.4% during the third quarter. Kestra Investment Management LLC now owns 675 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 16 shares during the period. AlphaCore Capital LLC raised its stake in shares of Regeneron Pharmaceuticals by 133.5% in the third quarter. AlphaCore Capital LLC now owns 1,602 shares of the biopharmaceutical company’s stock valued at $1,215,000 after purchasing an additional 916 shares in the last quarter. Finally, Leuthold Group LLC lifted its position in Regeneron Pharmaceuticals by 11.2% in the third quarter. Leuthold Group LLC now owns 10,303 shares of the biopharmaceutical company’s stock worth $7,812,000 after purchasing an additional 1,038 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the completion of the transaction, the executive vice president directly owned 13,134 shares of the company’s stock, valued at approximately $11,163,900. This trade represents a 8.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 7,439 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $970.46, for a total value of $7,219,251.94. Following the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,652,693.38. The trade was a 81.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 27,028 shares of company stock valued at $25,025,950. 6.97% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 28th. Bank of America increased their price objective on shares of Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the company a “buy” rating in a research note on Monday, November 2nd. Cantor Fitzgerald increased their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. Canaccord Genuity Group raised their price objective on shares of Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the stock a “buy” rating in a report on Wednesday, October 28th. Finally, Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 20th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $898.97.

Regeneron Pharmaceuticals News Summary

Investors following REGN have been watching these news items:

• Positive Sentiment: Regeneron collaborator Alnylam reported first-in-human results for CIDEBsiRNA in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD). A single dose rapidly normalized liver fat and improved markers of liver injury, providing encouraging early evidence for a potential treatment opportunity. Article: Alnylam collaborator Regeneron advances CIDEBsiRNA with promising first-in-human results
• Positive Sentiment: Soleo Health was selected as a specialty-pharmacy partner for Pasatru (garetosmab), Regeneron’s recently approved treatment for adults with the rare disorder fibrodysplasia ossificans progressiva. The partnership may support the drug’s distribution and patient access, although no sales impact was specified. Article: Soleo Health selected as a specialty pharmacy partner for Pasatru
• Neutral Sentiment: A Zacks article characterized REGN as a long-term value stock, but the summary provided no new company-specific developments or valuation details that would clearly explain near-term trading. Article: Why Regeneron is a top value stock for the long term

Regeneron Pharmaceuticals Trading Up 4.7%

Shares of REGN opened at $959.41 on Thursday. The company has a current ratio of 3.35, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market cap of $99.25 billion, a PE ratio of 19.18, a PEG ratio of 1.21 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 1 year low of $591.52 and a 1 year high of $991.73. The stock has a 50 day simple moving average of $811.95 and a 200-day simple moving average of $745.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating the consensus estimate of $16.51 by $3.56. The business had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. Regeneron Pharmaceuticals’s quarterly revenue was up 36.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $11.83 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.